Home  »  Companies   »  Allogene Therapeutics Inc. (ALLO) Stock Price and ...

Allogene Therapeutics Inc. (ALLO) Stock Price and Analyst Predictions

and a 36-month beta value of 0.75. Opinions on the stock are mixed, with 14 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”

The average price predicted for Allogene Therapeutics Inc. (ALLO) by analysts is $16.91, which is $11.9 above the current market price. The public float for ALLO is 84.55M, and at present, short sellers hold a 48.08% of that float. On May 25, 2023, the average trading volume of ALLO was 2.07M shares.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.

Sponsored

ALLO) stock’s latest price update

Allogene Therapeutics Inc. (NASDAQ: ALLO)’s stock price has plunge by -5.95relation to previous closing price of 6.05. Nevertheless, the company has seen a -7.03% plunge in its stock price over the last five trading sessions.

ALLO’s Market Performance

Allogene Therapeutics Inc. (ALLO) has seen a -7.03% fall in stock performance for the week, with a 1.61% gain in the past month and a -12.33% plunge in the past quarter. The volatility ratio for the week is 6.31%, and the volatility levels for the past 30 days are at 7.36% for ALLO. The simple moving average for the past 20 days is -5.40% for ALLO’s stock, with a -34.17% simple moving average for the past 200 days.

ALLO Trading at 4.25% from the 50-Day Moving Average

After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.47% of loss for the given period.

Volatility was left at 7.36%, however, over the last 30 days, the volatility rate increased by 6.31%, as shares surge +4.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.43% upper at present.

During the last 5 trading sessions, ALLO fell by -7.03%, which changed the moving average for the period of 200-days by -64.35% in comparison to the 20-day moving average, which settled at $6.03. In addition, Allogene Therapeutics Inc. saw -9.54% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ALLO starting from Bhavnagri Veer, who sale 3,000 shares at the price of $6.85 back on Feb 13. After this action, Bhavnagri Veer now owns 577,677 shares of Allogene Therapeutics Inc., valued at $20,550 using the latest closing price.

Bhavnagri Veer, the General Counsel of Allogene Therapeutics Inc., sale 3,000 shares at $7.04 during a trade that took place back on Jan 17, which means that Bhavnagri Veer is holding 580,677 shares at $21,120 based on the most recent closing price.

Stock Fundamentals for ALLO

Current profitability levels for the company are sitting at:

  • -138044.86 for the present operating margin
  • -6783.95 for the gross margin

The net margin for Allogene Therapeutics Inc. stands at -136885.60. The total capital return value is set at -38.19, while invested capital returns managed to touch -38.07. Equity return is now at value -50.20, with -41.40 for asset returns.

Based on Allogene Therapeutics Inc. (ALLO), the company’s capital structure generated 15.19 points at debt to equity in total, while total debt to capital is 13.18. Total debt to assets is 12.38, with long-term debt to equity ratio resting at 14.29. Finally, the long-term debt to capital ratio is 12.40.

When we switch over and look at the enterprise to sales, we see a ratio of 1,992.09, with the company’s debt to enterprise value settled at 0.21. The receivables turnover for the company is 0.05 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.70.

Conclusion

To sum up, Allogene Therapeutics Inc. (ALLO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.